Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 19/20 | 0.75 |
| ▸ | PDE1A | P54750 | 8/20 | 0.75 |
| ▸ | PDE1B | Q01064 | 8/20 | 0.75 |
| ▸ | PDE1C | Q14123 | 8/20 | 0.75 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.67 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.65 |
| ▸ | PDE6A | P16499 | 2/20 | 0.65 |
| ▸ | PDE6C | P51160 | 2/20 | 0.65 |
| ▸ | PDE2A | O00408 | 1/20 | 0.65 |
| ▸ | PDE6D | O43924 | 1/20 | 0.65 |
| ▸ | PDE9A | O76083 | 1/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | PDE6G | P18545 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 1/20 | 0.65 |
| ▸ | PDE4A | P27815 | 1/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14126907 | 0.91 | PDE5A (0.79) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL13435578 | 0.89 | PDE5A (0.67) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL15996153 | 0.88 | PDE5A (0.75) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL5902073 | 0.88 | PDE5A (0.75) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL20997440 | 0.87 | PDE5A (0.72) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL5902047 | 0.87 | PDE5A (0.72) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL5613 | 0.86 | PDE5A (1.00) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL30493634 | 0.86 | PDE5A (1.00) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL6501501 | 0.86 | PDE5A (0.74) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL8220166 | 0.86 | PDE5A (0.76) | PDE5APDE1APDE1BPDE1CHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2705753-A1 | 2-Phenyl-imidazolotriazinone compounds as PDE5 inhibitors | Surface Logix, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20100324037-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100093719-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20080176844-A1 | Pharmacokinetically Improved Compounds | SURFACE LOGIX, INC. | 2008-07-24 | — | — | US | disclosed |
| WO-2008024494-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2006089276-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| WO-2006089275-A2 | METHODS OF MAKING PHARMACOKINETICALLY IMPROVED COMPOUNDS COMPRISING FUNCTIONAL RESIDUES OR GROUPS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS | SURFACE LOGIX, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093719-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC7A1, HRH4 | PDE5A 2425/4885PDE1A 4351/4885PDE1B 3529/4885 |
| US-20080176844-A1 | Pharmacokinetically Improved Compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC7A1, HRH4 | PDE5A 2425/4885PDE1A 4351/4885PDE1B 3529/4885 |
| US-20100324037-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ABCG2, SLC10A1, SLC10A2 | PDE5A 1474/4885PDE1A 3065/4885PDE1B 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.